Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- Pacific Mind HealthPacific Mind Health Releases Free Guide to Help People Catch Overstimulation at Work Before It PeaksPacific Mind Health has released a FREE downloadable guide When Work Feels Like Too Much designed to help people recognize the early signs of overstimulation on the job and respond before they reach full overload. Noise, lighting, notifications,...
- Flo Health Inc.Flo Health Finds Women's Perimenopause Symptoms and Concerns are Still Being DismissedA long history of disregarding women's midlife experiences is still prevalent today; 66% report being told perimenopause symptoms are "just a part of getting older"1 — Women seeking treatment for perimenopause symptoms often navigate a system that...
- Lakewood-Amedex Biotherapeutics Inc.Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3Clinical and Corporate Highlights Successfully listed on the Nasdaq Capital Market under the ticker symbol LABT, marking a significant milestone in the Company's evolution Strengthened balance sheet through completion of a $7.5 million private placement to support continued clinical...
- Hoag Hospital Irvine Sun Family Campus Now Open, Introducing a New Model for Specialized Care in Orange CountySix-Building Expansion Brings Specialized Hospital and Outpatient Care Together on One Integrated Campus to Advanced Care in Orange County
- KFSH Recognized in Newsweek’s World’s Best Specialized Hospitals 2027King Faisal Specialist Hospital & Research Centre (KFSH) has reinforced its position as a global healthcare leader, earning prominent placement in Newsweek’s prestigious World’s Best Specialized Hospitals 2027 ranking. Across its campuses in Riyadh and Jeddah, KFSH has been recognized in 10 medical specialties, a powerful reflection of the institution's world-class clinical standards and global standing among medical professionals.
- SAPEyes on the Future—From Eyewear to Smart WearablesCompanies: SAPEssilorLuxottica operates at the intersection of medical technology, consumer fashion, and retail.
- ŌURAŌURA Announces Launch of Initial Public OfferingCompanies: Jefferies Financial GroupMorgan StanleySAN FRANCISCO, September 21, 2026--ŌURA, a leading health intelligence platform and maker of the world’s smallest smart ring, today announced that it has launched its initial public offering of 50,000,000 shares of its common stock. The offering consists of 13,500,000 shares offered by Oura and 36,500,000 shares offered by certain of Oura’s existing stockholders. In addition, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 7,500,000 share
- Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity ScienceBELGRADE, Serbia, September 21, 2026--BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science.
- IntelliguardHospitals May Be Sitting on Millions in Untapped Medication Cost SavingsCOLUMBUS, Ohio, September 21, 2026--Intelliguard, a leader in RFID-enabled medication inventory management, today announced the launch of its new Interactive ROI Calculator, designed to help hospital and health system leaders quickly estimate the potential five-year financial impact of improving how medications are managed across their organizations.
- Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)DUBLIN, September 21, 2026--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist in development for the treatment of attention-deficit hyperactivity disorder (ADHD). The study evaluated the safety and tolerability (primary objective) and pharmacokinetics (PK) and pharmacodynamics (PD) of ALKS 7290 in healthy volunteers (n=88) and in adults with ADHD (n
- Iambic Launches Enchant v3 – Molecular Superintelligence Designed to Advance End-to-End Drug Discovery & DevelopmentSAN DIEGO, September 21, 2026--Iambic, a clinical-stage life science and technology company developing novel medicines using its AI-driven platform, today unveiled Enchant v3, the next generation of its multimodal transformer model built to advance end-to-end drug discovery and development. Enchant is the ‘brain’ behind Iambic’s molecular superintelligence platform that, when combined with Iambic’s in-house high-throughput experimental chemistry and biology capabilities, can learn from and predi
- Therapy Has Become the Default Answer to Everyday Stress and Social Connection, and Employers Are Paying for ItSAN FRANCISCO, September 21, 2026--New global research from Modern Health, a leading global workplace mental health platform, finds that therapy has become the default response not only to clinical mental health needs but to everyday work stress and the simple need for someone to talk to, and employers are often financing a level of care many employees say they didn’t need.